Chronic spontaneous urticaria is a medical condition with active clinical research programs worldwide.

14 total trials for this combination

Showing top 10 of 14 trials

Trials

NCT ID	Title	Status	Phase
NCT02477332	Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU	COMPLETED	PHASE2
NCT04210843	Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab	TERMINATED	PHASE3
NCT02649218	A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients	COMPLETED	PHASE2
NCT04833855	Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria	COMPLETED	PHASE2
NCT05513001	An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib	ACTIVE_NOT_RECRUITING	PHASE3
NCT05030311	A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines	COMPLETED	PHASE3
NCT03926611	This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines	COMPLETED	PHASE2
NCT04180488	Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)	COMPLETED	PHASE3
NCT05107115	Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine	COMPLETED	PHASE2
NCT03580356	A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.	COMPLETED	PHASE3

Related Pages

All Chronic spontaneous urticaria trials All trials in Yokohama, Japan